Campbell, CA – Today, life science solutions company Saama announced that Apratim Purakayastha, Ph.D., has joined the company as Advisor.
In this role, Apratim Purakayastha (AP) will use his expertise to support Saama in all aspects of product development, from conception to go-to-market.
“AP’s product and technology expertise are tremendous assets to Saama as we forge ahead and develop more products and services that will accelerate getting medications to patients,” stated Vivek Sharma, Chief Executive Officer of Samma. “We are thrilled to welcome AP as an advisor and even more excited about the impact he will have on our customers and patients.”
Since 2016, AP has held the title, Chief Product and Technology Officer at Skillsoft. During his tenure, AP built a market-leading state-of-the-art learning platform called Percipio. The platform generated 1.5B in investment interest in Skillsoft and AP received the lion share of credit for Skillsoft’s IPO in June 2021. Today, Skillsoft is positioned as the world’s leading corporate learning company, offering the largest library of courseware and micro-learning assets in the academic world.
Prior to joining Skillsoft, AP was Group President at ACI Worldwide and ran the corporation’s SaaS payments P&L. AP began his career at IBM in research and later became a Director at IBM where he built the first commercial SaaS offering called LotusLive.
Throughout AP’s career in software development, he has directed several B2B SaaS product strategies, product design and executions, and product go-to-market.
AP currently serves on the board of directors for William Clarence, a London-based education consultancy. AP earned his B.S. in Computer Science from Jadavpur University in India, a M.S. in Computer Science from Washington State University and his Ph.D., from Duke University.
Saama develops life science solutions that accelerate clinical and commercial development. Today, more than 50 biotech companies – including many of the top 20 pharmaceutical companies – use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform to accelerate more than 1,500 studies, including the clinical trial that led to the world’s first COVID-19 vaccine. LSAC’s rich applications facilitate unprecedented and authoritative oversight and automation of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring treatments to patients sooner. Discover more at www.saama.com and follow @SaamaTechInc on Twitter.